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ABSTRACT 
Kelsey A. Ludwig: Social Cognition Psychometric Evaluation (SCOPE) for Early Psychosis 
(Under the direction of David L. Penn) 
 
Social cognition is an important outcome in schizophrenia research.  Unfortunately, there 
has been a lack of consensus regarding which measures of social cognition best capture this domain 
of functioning.  The Social Cognition Psychometric Evaluation (SCOPE) study was developed to 
address the need for a battery of measures that have sound psychometric properties and can be 
implemented in clinical trials for individuals with chronic schizophrenia.  The current study expands 
upon the SCOPE study by examining the psychometric properties of the eight candidate measures 
administered to individuals early in the course of psychosis.  Thirty-eight stable outpatients with first 
episode psychosis (FEP) and thirty-nine healthy controls completed the battery at baseline and one-
month follow-up assessments.  The SCOPE battery was evaluated on a collection of psychometric 
properties, including: (1) Reliability – including test-retest and internal consistency, (2) Between 
group differences – including direct comparisons between first episode patients, the chronic 
schizophrenia sample from SCOPE, and both demographically-matched control groups, (3) Utility as 
a repeated measure, (4) Convergent and discriminant validity, (5) Relationship to social and 
occupational functioning, (6) Incremental validity – variance in functioning beyond neurocognition, 
and (7) Feasibility – including practicality of administration and tolerability.  Social cognition 
accounted for substantially more variance in functional outcome than neurocognition.  Participants 
with FEP outperformed chronic schizophrenia patients on the majority of candidate measures of 
social cognition.  Only one measure, the Hinting task, displayed adequate psychometric properties to 
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be recommended for use in clinical research with first episode psychosis.  The remaining candidate 
measures would require modifications before implementation or cannot be recommended for use in 
clinical research with first episode psychosis. 
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INTRODUCTION 
Social cognition, defined as the mental processes underlying people’s capacity to 
perceive, process and comprehend social information, is related to quality of life, daily living 
skills and occupational functioning in schizophrenia (Frith, 2008; Green, Hellemann, Horan, Lee, 
& Wynn, 2012; Kunda, 1999; Mancuso, Horan, Kern, & Green, 2011).  Social cognition 
accounts for additional variance in functioning than various cognitive factors (Brϋne, 2007), and 
mediates the relationship between neurocognition and functioning in psychosis (Fett et al., 2011; 
Schmidt, Mueller & Roder, 2011). Based on its relation to functional outcome, social cognition 
in schizophrenia has garnered considerable research interest over the past few decades and is 
increasingly considered a viable target for treatment (Couture, Penn, & Roberts, 2006; Fett et al., 
2011; Green & Leitman, 2008; Penn, Corrigan, Bentall, Racenstein, & Newman, 1997). 
Despite burgeoning interest in studying social cognition, studies investigating these 
constructs vary greatly in the tasks employed, many of which may lack a strong empirical 
foundation and involve unknown or questionable psychometric properties (Couture & Penn, 
2012; Fett et al., 2011; Savla, Vella, Armstrong, Penn, & Twamley, 2013; Thompson, 
Bartholomeusz, & Yung, 2011).  The absence of a validated battery of social cognitive measures 
is problematic as inadequate and inconsistent measurement can jeopardize the validity, 
reproducibility, and comparability of findings, and may lead to effective treatments being 
discarded or ineffective treatments pursued (Drost, 2011).  
To address this need, an ongoing NIMH project called the Social Cognition Psychometric 
Evaluation (SCOPE) study was initiated (Pinkham et al., 2014; Pinkham et al., 2015).  SCOPE is 
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a multiphase project that involves identifying the currently accepted domains of social cognition, 
selecting the best available measures to assess these domains, and administering tasks to a large 
sample of stable outpatients with schizophrenia and demographically-matched controls.   
Findings from the initial validation study suggested the Bell-Lysaker Emotion 
Recognition Task (BLERT; Bell, Bryson, & Lysaker, 1997), Penn Emotion Recognition Task 
(ER-40; Kohler et al., 2003), Reading the Mind in the Eyes Test (Eyes; Baron-Cohen, 
Wheelwright, Hill, Raste, & Plumb, 2003), The Awareness of Social Inferences Test (TASIT; 
McDonald, Flanagan, Rollins, & Kinch, 2003), and Hinting Task (Hinting; Corcoran, Mercer, & 
Frith, 1995), displayed acceptable reliability and validity for implementation in clinical research.  
Remaining measures, including: Ambiguous Intentions Hostility Questionnaire (AIHQ; Combs, 
Penn, Wicher, & Waldherer, 2007), Relationships Across Domains (RAD; Sergi et al., 2009), and 
Trustworthiness Task (Trust; Adolphs, Tranel, & Damasio, 1998), demonstrated weaker 
characteristics and were deemed inadequate for use in clinical trials targeting social cognition 
(Pinkham et al., 2015), although subsequent findings support continued development and use of 
the AIHQ Blame Score (Buck et al., 2017, in press). 
Importantly, SCOPE included a predominantly middle-aged, chronic sample typical of 
many treatment studies.  There is some debate as to whether first episode psychosis (FEP) and 
chronic schizophrenia patients should exhibit the same types and degree of social cognitive 
impairment (Savla et al., 2013; Thompson, Bartholomeusz, & Yung; 2011; Ventura et al., 2015).  
Some research suggests attenuated or unremarkable deficits earlier in the course of illness (An et 
al., 2010; Bora & Pantelis, 2013; Romero-Ferreiro et al., 2016; Sprong et al., 2007), though 
findings are mixed (Barkl et al., 2014; Green et al., 2012; Horan et al., 2012; Zaytseva, Burova, 
Garakh, & Gurovich, 2013).  FEP samples may also be more heterogeneous than many chronic 
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schizophrenia samples (Birchwood et al., 1998), and differences in social cognition across phase 
of illness may stem from variations in clinical stability (Bora & Pantelis, 2013; Green et al. 
2012) and age-related changes in neurocognitive abilities (Hartshorne & Germine, 2015).  
Consequently, the results of SCOPE may not accurately represent younger individuals with FEP. 
The purpose of the current study was to extend Pinkham et al.’s (2015) psychometric 
investigation of the SCOPE battery with a younger FEP sample.  Paralleling SCOPE, we report 
on: (1) Reliability: test-retest, internal consistency, (2) Between-group differences: including 
directly comparing first episode patients, chronic schizophrenia patients from SCOPE, and both 
demographically-matched control groups,  (3) Utility as a repeated measure, (4) Convergent and 
discriminant validity, (5) Relationship to social/occupational functioning, (6) Incremental 
validity: variance in functioning beyond neurocognition, and (7) Feasibility: practicality of 
administration and tolerability. 
Investigations comparing first episode and chronic schizophrenia patients frequently 
involve control groups that differ in important demographics from at least one clinical group 
(Romero-Ferreiro et al., 2016).  This thesis provides a direct comparison of performance on the 
social cognition battery when administered to chronic schizophrenia, first episode psychosis, and 
their respective, demographically matched control groups.  Recommendations regarding 
suitability of the candidate measures for implementation in clinical research with first episode 
psychosis outpatients have also been provided. 
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METHOD 
Participants 
 The study took place at the University of North Carolina at Chapel Hill.  FEP patients 
were primarily recruited from the Outreach and Support Intervention Services (OASIS) clinic in 
Carrboro, NC.  Patients required a diagnosis of schizophrenia, schizoaffective disorder, 
schizophreniform disorder, or psychosis NOS, confirmed by the Structured Clinical Interview for 
DSM-IV Axis-I Disorders, Patient Edition (SCID-P; First et al., 2002). OASIS clinicians and/or 
a trained research assistant at UNC-CH conducted all diagnostic interviews.   
Participants were excluded if diagnosed with psychosis for greater than five years, or had 
been hospitalized within the last two-months.  Deterioration is most common before illness onset 
and during the first few years of psychosis (Birchwood et al., 1998).  Furthermore, evidence 
indicates a subsequent illness “plateau,” during which a level of relative stability is established 2-
5 years after illness onset (Srihari et al., 2012). Thus, a cut-off of five years for illness duration 
was used.  Participants were required to be on a stable medication regimen for a minimum of the 
two-month hospitalization-free period, though they were not excluded if psychiatrically stable 
while not receiving antipsychotics. 
 Control participants were recruited through community flyers and online advertisements.  
Controls were selected for similarities in age/gender to FEP outpatient participants.  Controls 
were precluded from participation for meeting criteria for any Axis I/II disorder according to the 
DSM-IV, or if they had a first-degree family member with a history of psychosis.  Chronic 
outpatient and matched control participants from the original SCOPE study were included in 
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analyses examining possible performance differences across stage of illness only.  For detailed 
demographic information, please refer to Pinkham et al., 2015. 
 All participants were considered ineligible based on: 1) presence/history of mental 
retardation, 2) presence/history of brain injury and/or neurological disorder (e.g., seizures, 
multiple sclerosis), 3) sensory limitation that would interfere with assessment (e.g., 
blindness/deafness), and/or 4) evidence of non-nicotine substance dependence in the past six-
months, with substance use not being exclusionary.  Evidence of substance dependence was 
collected from patients’ healthcare providers, via chart review, and/or through substance use 
disorder modules from the SCID (DSM-IV; First et al., 2002). 
Measures 
Measures of Social Cognition 
We administered identical versions of the eight candidate measures of social cognition 
from the initial psychometric evaluation (Pinkham et al., 2015), including: 
Attributional style 
The Ambiguous Intentions and Hostility Questionnaire, abbreviated version (AIHQ) 
measures the extent to which an individual tends toward a hostile or aggressive interpretation of 
everyday situations or common occurrences (Combs et al., 2007).  For this task, participants 
were asked to read a set of five ambiguous situations and imagine how each scenario might 
actually happen to them.  They were first asked to provide (a) a brief explanation for why the 
person in the scenario acted the way they did.  Then, they answered three Likert-style questions 
to gauge (b) to what extent the participant believed the person in the story behaved the way they 
did on purpose (from 1 = "Definitely No" to 6 = "Definitely Yes”), (c) how angry the participant 
would feel (from 1 = "Not at All Angry" to 5 = "Very Angry”), and (d) the degree to which 
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he/she would blame the other person (from 1 = "Not at All" to 5 = "Very Much”).  Finally, they 
were asked to provide (e) a brief description of a probable behavioral response (i.e., what they 
would do about the situation).   
Likert-style questions, averaged per item and aggregated across five scenarios, comprise 
a Blame Score (BS, range: 3-16).  Two independent raters with high concordance (ICCs ranged 
.834 to .967 for the individual items) coded participants’ responses to the two open-ended 
questions (items a and e) to calculate Hostility Bias (HB, range: 1-5) and Aggression Bias (AB, 
range: 1-5).  Higher scores reflect more hostile or aggressive attributional styles. 
Emotion processing 
The Bell Lysaker Emotion Recognition Task (BLERT) measures an individual’s ability to 
correctly identify the feeling or emotion expressed during a series of 21 short video clips (Bell, 
Bryson, & Lysaker, 1997).  Participants were asked to view 10-second recordings of a male actor 
providing facial, vocal, and bodily indications of seven distinct emotions: sadness, anger, 
disgust, happiness, surprise, fear or no emotion.  The dependent measure was the total number of 
correct responses, ranging from 0 to 21. 
The Penn Emotion Recognition Test (ER-40) examines the ability of individuals to 
distinguish between various facial expressions of emotion (Kohler et al., 2003).  In this task, 
participants are instructed to choose which feeling or emotion is being expressed in a set of forty 
photographic stimuli.  The individuals represented are ethnically diverse, stem from multiple age 
groups, and include an equal number of male-female actors.  Photographs are balanced for each 
emotion category (i.e., happy, sad, anger, fear, no emotion) and vary in terms of intensity of the 
expression.  Participants were shown each photograph sequentially and asked to select an 
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emotion before moving onto the next slide.  The dependent variable was the total number of 
correct responses, ranging from 0 to 40. 
Theory of mind 
The Reading the Mind in the Eyes Test (Eyes) measures how well a person is able to 
conceptualize and discern the mental state of another person based on a set of static visual 
stimuli (Baron-Cohen et al., 2001).  The set of stimuli is comprised of 36 black-and-white 
photographs depicting the eye-region of various actors’ and actresses’ faces.  Participants were 
shown each stimulus separately and asked to choose the most appropriate of four possible mental 
state descriptors.  Participants were provided with a glossary to peruse whenever he or she felt 
unclear about the meaning of particular term.  The dependent measure was the total number of 
correct responses, ranging from 0 to 36. 
The Awareness of Social Inferences Test, Part III (TASIT) assesses the extent to which an 
individual comprehends interpersonal contextual cues; i.e., sarcasm or dishonesty (McDonald et 
al., 2003).  Participants viewed 16 short video clips depicting conversations between two or more 
people, and answered four basic questions about each exchange.  The questions gauged the 
participant’s understanding of the beliefs, meanings, intentions and feelings expressed by the 
actors.  All participants viewed vignettes from Form A during the first assessment and watched 
clips from Form B during the second assessment.  The dependent variable was the total number 
of correct responses, ranging from 0 to 64. 
 The Hinting Task (Hinting) examines the ability of a participant to decipher the true 
meaning of indirect verbal cues, or hints (Corcoran, Mercer, & Frith, 1995).  The experimenter 
reads a series of 10 brief conversations to the subject.  Each conversation involves one of two 
characters hinting something to the other person, and the participant is asked to provide an 
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explanation of each indirect verbal cue.  If the subject misinterprets the situation, an additional 
clue is given so as to provide the participant the opportunity to earn partial credit.  The dependent 
measure was the total number of correct responses, ranging from 0 to 20. 
Social perception 
 The Relationships Across Domains, abbreviated version (RAD) is a paper-and-pencil 
based measure of social perception (Sergi et al., 2009). The abbreviated version includes a set of 
fifteen vignettes that describe a male-female relationship to which participants were asked to 
answer three yes/no questions related to each dyad.  This task was used to measure participants’ 
implicit understanding of social relationships and ability to predict others’ behaviors according to 
four relational models that influence social behavior: communal sharing, authority ranking, 
equality matching, and market pricing.  The dependent variable was the total number of correct 
responses, ranging from 0 to 45. 
Novel 
 The Trustworthiness Task (Trust), labeled novel as it does not fit neatly under any of the 
four currently accepted domains of social cognition, gives an indication of individuals immediate 
social judgments of unknown others (Adolphs, Tranel, & Damasio, 1998).  Participants were 
shown a set of static visual stimuli, 42 black-and-white photos of strangers’ faces, and were 
asked to judge the extent to which he/she would trust the person in the photograph.  They 
provided ratings on a 7-point scale (from -3 = “Very Untrustworthy” to +3 = “Very 
Trustworthy”).  Rather than summing the number of “correct” responses, the average rating of 
trustworthiness provided for the set of visual stimuli served as the dependent measure. 
Neurocognitive Measures 
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Neurocognition was measured using a subset of The MATRICS Consensus Cognitive 
Battery (MCCB): Trail-Making Test-Part A, BACS-Symbol Coding, Category Fluency-Animal 
Naming, Letter-Number Span, and Hopkins Verbal Learning Test-Revised (Nuechterlein et al., 
2008).  Consistent with SCOPE, subtests were selected according to correlations with composite 
scores of neurocognitive performance (Keefe et al., 2006; Pinkham et al., 2015).  With the 
exception of the Trails task, for which reverse scores were used, higher scores reflect better 
performance on the selected measures of the MCCB.  Neurocognitive scores were calculated by 
a) computing t-scores for each subtest using the following formula: T = (X – MFEP) / (s / √(nFEP), 
and b) computing a standardized composite score by taking the average of the t-scores for each 
subtest: MCCBComposite = (1/5)(TLNS – TTrails + TSym + THVLT-R + TAnimals).   
 The Wide Range Achievement Test (WRAT-3) Reading subscale assesses an individual’s 
reading ability (Weickert et al., 2000).  For the purposes of this study, this measure was used to 
supplement the MCCB and provide an estimate of IQ. 
Measures of Social and Occupational Functioning 
 Community and daily living skills were assessed using The UCSD Performance-Based 
Skills Assessment-Brief (UPSA-B; Mausbach et al., 2007), a performance-based measure of 
functional capacity, and The Specific Level of Functioning Scale, Self-Report (SLOF; Schneider 
& Struening, 1983). 
 Social skills were assessed with The Social Skills Performance Assessment (SSPA; 
Patterson et al., 2001). Participant and experimenter acted out two social situations: meeting a 
new neighbor and persuading a landlord to fix a bathroom leak.  Scenes were audio-recorded and 
rated by a blind-to-diagnosis, expert coder involved in all previous ratings for SCOPE.  
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The mean score across both role-plays was used as the dependent measure, with a possible range 
from 1 to 5. 
Symptomatology 
 The Positive and Negative Syndrome Scale (PANSS) is an interview-based assessment 
that evaluates symptom severity for people with psychosis (Kay, Opler, & Fiszbein, 1997).  The 
rating scale, comprised of three sub-scales, measures positive symptoms, negative symptoms and 
symptoms of general psychopathology. 
Feasibility 
 Practicality was operationalized as administration time, which was measured using an 
electronic stopwatch.  Research assistants were instructed to begin timing immediately upon 
initiating a social cognitive task, and to discontinue timing upon completion of the test. 
To assess tolerability, participants were asked to rate each measure on a Likert-type scale 
that ranged from 1 (very unpleasant) to 7 (very pleasant) immediately following the completion 
of each social cognitive measure.  Ratings of 4 indicated a neutral response of neither pleasant 
nor unpleasant. 
Procedure 
 Participants completed two assessments: baseline and a retest assessment scheduled to 
occur approximately 4 weeks later.  With the project approved by the UNC-CH Institutional 
Review Board, participants provided signed informed consent and completed social cognitive, 
neurocognitive, and functional outcome measures at baseline. Task block order and the order of 
individual tasks within the social cognitive battery were counterbalanced.  A rater trained using 
the same procedures employed in SCOPE conducted diagnostic and symptomatic interviews.  
Symptoms were reassessed in patients at retest.  With the exception of TASIT, for which an 
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alternative form was available, identical social cognitive tasks were administered at retest, in a 
different counterbalanced order.  In accord with the original SCOPE protocol, Version-A was 
administered at baseline, Version-B at retest. 
Statistical Analyses Overview 
 Data analyses were performed using the Statistical Package for the Social Science (SPSS) 
version 23.  Statistical significance was defined as p < .05.   
We followed the psychometric validation process employed for the initial validation 
study (Pinkham et al., 2015).  Score distributions of the social cognitive measures were inspected 
for normality by examining skew and kurtosis statistics and visually inspecting histograms.  
Though no measures were transformed, one participant in the clinical group was an outlier on the 
BLERT (> 3SD from the mean).  Consequently, these data were excluded from further analyses. 
Test-Retest Reliability and Internal Consistency 
Pearson’s r correlation coefficients were calculated for each social cognition measure to 
examine test-retest reliability.  Pearson’s r values greater than or equal to 0.6 for test-retest 
reliability were considered adequate (Kraemer et al., 2012; Pinkham et al., 2015).  To determine 
the extent to which items within a measure are related, Cronbach’s alpha was used to determine 
internal consistency for each task.  Alpha values greater than or equal to 0.8 were regarded as 
acceptable (Nunnally & Bernstein, 1994). 
Between Group Differences 
To directly determine the extent to which phase and clinical group membership 
contributed to performance on each social cognitive measure, we conducted a 2x2 between-
subjects factorial ANOVA.  Group (clinical sample or healthy controls) served as one factor and 
phase (chronic or first episode study) was included as the second independent variable.  The 
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influences of participant age and estimated IQ were controlled for in the analyses.  Consistent 
with Pinkham et al., subjects were removed from the analyses if they were identified as outliers 
in their respective group, or if a subject did not complete a particular task.  This process was 
carried out separately for each candidate measure in the SCOPE battery. 
 Post hoc analyses probing interactions and main effects involved conducting pairwise 
comparisons using the Bonferroni correction method.  Cohen’s d values were used to measure 
the magnitude of differences in performance between FEP patients, chronic patients, and both 
demographically matched control groups.  Effect sizes were evaluated according to the ranges 
recommended by Cohen (1988): small (d=0.2), medium (d=0.5), and large (d=0.8). 
Utility as a Repeated Measure 
The clinical utility of these tasks as repeated outcome measures was analyzed by 
assessing evidence of practice effects and any indication of floor/ceiling effects.  As participants 
completed each task twice, we conducted paired-samples t-tests and calculated Cohen’s dz 
values.  Effect sizes indicating statistically significant improvement (Cohen’s dz values greater 
than .30) between the first and second administrations of a particular task were considered 
suggestive of clinically relevant practice effects.  The number of participants scoring at or below 
chance levels operationalized floor effects.  The number of participants earning a perfect score 
on a particular task operationalized ceiling effects. 
Convergent and Discriminant Validity 
Convergent validity was examined to determine the extent to which the eight social 
cognitive tasks were related.  We calculated correlations between participants’ total scores on the 
social cognitive tasks completed at baseline.  We reported statistically significant associations 
between measures, with an emphasis on moderate to strong correlations between tasks purported 
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to assess capabilities in the same domain of social cognition.  To examine discriminant validity, 
we reported on correlations between participants’ total scores on the social cognition measures 
and composite score on the MATRICS Consensus Cognitive Battery (MCCB) administered at 
baseline. 
Relationship to Social and Occupational Functioning 
 To investigate the relationship between social cognition and functional outcome, we 
computed correlations between social cognitive capacity and performance on functional outcome 
measures, including: the UCSD Performance-Based Skills Assessment (UPSA), the Social Skills 
Performance Assessment (SSPA), and the Specific Level of Functioning (SLOF) scale. 
Incremental validity – Variance in Functioning beyond Neurocognition  
To assess incremental validity beyond neurocognitive abilities, we constructed a 
regression model in blocks.  The first block consisted of the composite score on the MATRICS 
Consensus Cognitive Battery (MCCB).  To examine the increase in predictive power of social 
cognition, a second block was created that included all social cognitive measures shown to be 
significantly related to each functional outcome measure.  We used R-squared and adjusted R-
squared statistics to determine the extent to which the addition of social cognition accounted for 
variance in functional outcome beyond neurocognition. 
Feasibility – Practicality of Administration and Tolerability   
Descriptive statistics were used to assess practicality of administration and tolerability for 
patients.  We provided mean and standard deviation values for practicality, operationalized as 
administration time, including instruction review and task completion; and tolerability, 
operationalized as self-report ratings of enjoyability on a Likert-type scale from 1 (very 
unpleasant) to 7 (very pleasant). 
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Decision-making Process Regarding SCOPE Battery for First Episode Psychosis 
To determine the suitability of the SCOPE battery for FEP, we emphasized test-retest 
reliability, relationship to functional outcome, and ability to distinguish patient and control 
performance.  We followed a similar process to Pinkham et al. (2015) such that we consulted 
with the principal investigators of SCOPE before making final recommendations.  We also used 
the following groupings to meaningfully classify candidate measures into three disparate 
categories: 
Acceptable at Present signifies the measure displayed acceptable reliability and validity 
in the current study, and would not require modifications before use.  To be considered 
acceptable for implementation in clinical trials at present, a measure displayed adequate test-
retest reliability, demonstrated a significant relationship with at least one functional outcome 
measures, and effectively distinguished between patients and controls.  
Acceptable with Concerns indicates specific attributes of the task were concerning and 
warrant further investigation before implementation in clinical research.  Areas of concern 
included failure to distinguish early psychosis patients and nonclinical controls, as well as 
intolerability for patients.  Although feasibility is an important indicator of the utility of a 
measure, a task was not precluded from recommendation solely for requiring additional time to 
administer and/or for being less enjoyable provided that the measure also contributed valuable 
information. 
 Currently Unacceptable signifies a task displayed weak psychometrics overall and 
cannot be recommended for use in clinical research with this population.  Inadequacies included 
poor test-retest reliability and/or limited relation to functional outcome. 
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RESULTS 
Participants 
Thirty-eight FEP patients and 39 age- and gender-matched controls completed the 
baseline assessment.  Thirty-five patients and 36 controls returned to complete visit two.  
Average time between administrations was comparable for both groups (MFEP=33.08 days, 
SD=5.65; MHC=31.61 days, SD=4.81; t(70)=-1.190, P=.238).  FEP patients and controls did not 
differ in regard to gender, race, ethnicity, age, or estimated IQ (see Tables 1a and 1b).  FEP 
patients completed significantly fewer years of education than controls, whereas patients’ parents 
completed significantly more years of education than the control sample.  
Separate 2x2 factorial ANOVAs were conducted to examine differences demographic, 
clinical and cognitive characteristics across studies.  Results revealed a significant main effect of 
Phase on age (F (1, 356) = 131.02, p < 0.001) and IQ (F (1, 356) = 45.56, p < 0.001).  Regarding 
education, analyses also revealed significant main effects of Phase (F (1, 356) = 45.47, p < 
0.001) and Group (F (1, 356) = 17.37, p < 0.001).  Participants involved in SCOPE-FEP were 
significantly younger, better educated, and had higher IQ than participants in the original SCOPE 
study (Tables 1a and 1b).  Educational attainment also varied across groups, with controls (Medu-
hc = 14.0 years, SD = 1.7, n = 143) completing significantly greater years of education than 
patients (Medu-scz&fep = 12.9 years, SD = 1.8, n = 217). 
No statistically significant Phase x Group interactions were found for age (F (1, 356) = 
0.71, p > .05), IQ (F (1, 356) = 0.01, p > .05), or education (F (1, 356) = 2.21, p > .05).  
An additional 2x2 factorial ANOVA examining patient symptoms across phase (chronic 
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or first episode study) and assessment visit (baseline or retest) was conducted.  A significant 
main effect was found for phase (F (1, 215) = 12.77, p < 0.001), but not assessment type (F (1, 
206) = 1.72, p > .05).  Post hoc analyses revealed FEP patients presented with more symptoms 
than chronic patients at baseline and retest (Tables 1a and 1b).  Significant relationships between 
symptoms and social cognition were found for only two candidate measures: the TASIT (r = -
.156, p < .05) and Trust task (r = -.149, p < .05). 
Test-Retest Reliability  
Hinting, RAD, and AIHQ (BS) demonstrated acceptable levels of test-retest reliability 
(Pearson’s r values ≥ 0.6) for FEP patients.  BLERT, ER-40, Eyes, RAD, and two AIHQ 
subscales (AB/BS) showed adequate values among younger controls (Table 2). 
Internal Consistency 
For FEP patients, few candidate measures approached/exceeded acceptable Cronbach’s 
alpha values (α ≥ 0.8).  Exceptions included Trust (.943), TASIT (.795) and AIHQ-BS (.857).  
Internal consistency was generally lower for controls, with values for all tasks below target 
standards (Table 2). 
Group Differences  
Significant main effects of Phase (chronic or first episode study) were found for the Eyes, 
Hinting, RAD, TASIT and Trust tasks (Table 3b).  Controlling for age and estimated IQ, patient 
and control participants in SCOPE-FEP outperformed clinical and non-clinical participants in the 
original SCOPE study on the Eyes, Hinting, RAD, TASIT and Trust tasks.  Results also revealed 
significant main effects of Group (patients or controls) for the AIHQ (HB/BS), BLERT, ER40, 
Eyes, Hinting, RAD, and TASIT (Table 3b).  With the exception of the Trust task and one 
subscale of the AIHQ (AB), control participants outperformed patients on all measures in the 
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candidate battery when controlling for relevant covariates.  Findings indicated statistically 
significant Phase x Group interactions for several tasks, including: the AIHQ (BS), BLERT, 
Eyes and RAD (Table 3b).  All F-statistics and mean performance values have been summarized 
in Tables 3a and 3b. 
Post hoc pairwise comparisons were conducted using a Bonferroni correction to further 
examine statistically significant main effects and interactions.  Results revealed that chronic 
patients scored significantly worse on the AIHQ (BS), BLERT, Eyes and RAD than first episode 
patients and both control groups when controlling for the effects of age and estimated IQ.  Scores 
on the AIHQ (BS), BLERT, Eyes and RAD for the remaining three groups did not significantly 
differ from one another.  Additional analyses revealed performance differences between FEP 
patients and their demographically matched control group on only two measures: the Hinting and 
TASIT.  Similarly, performance between FEP patients and the control sample from SCOPE 
significantly differed on the ER40 only. 
Effect sizes (Cohen’s d) indicating magnitude of differences between chronic patients 
and the remaining three groups were moderate-to-large for two subscales of the AIHQ (HB/BS) 
(range: d = .65 to .90), BLERT (range: d = .76 to 1.43), ER40 (range: d = .71 to .94), Eyes 
(range: d = .67 to 1.33), and Hinting (range: d = .66 to 1.37); and large for the RAD (range: d = 
.93 to 1.85) and TASIT (range: d =1.05 to 2.12).  Similarly, performance differences between 
FEP patients and their demographically-matched control group were large for both the Hinting (d 
= .81) and TASIT (d = 1.04).  Though significant, the magnitude of the difference between FEP 
patients and SCOPE controls on the ER40 was small (d = .21). 
Utility as a Repeated Measure  
 18
For FEP patients, three of eight measures demonstrated statistically significant 
differences between assessments (Tables 4a and 4b).  Patient performance on ER-40 and Hinting 
improved, whereas TASIT performance worsened from baseline to retest.  Effect sizes were 
moderate (Cohen’s dz range: .414-.642).  Compared to the initial psychometric evaluation 
(Pinkham et al., 2015), floor/ceiling effects were less evident for this sample. A maximum of two 
patients (<6%) received perfect or chance-level scores on any measure. 
Alternatively, younger controls performed significantly better on BLERT, ER-40, RAD, 
and AIHQ-BS at retest.  Similar to FEP patients, control performance across versions of the 
TASIT worsened significantly from baseline to retest.  Practice effects varied, with effect sizes in 
the small-to-medium range (Cohen’s dz range: .212-.732).  Only one control scored at/below 
chance levels on any task (Eyes) during either visit. 
With the exception of the second administration of BLERT and first administration of 
Hinting, <8% of controls scored at ceiling for any candidate measure.  Five (12.8%) received 
perfect scores on BLERT (visit 2), whereas four (10.3%) scored at ceiling on Hinting (visit 1). 
Convergent and Divergent Validity 
Correlations between candidate measures of social cognition, as well as associations 
between these tasks and the neurocognitive battery when administered to a younger sample have 
been provided in Tables 5a and 5b.  With the exception of the Eyes task, remaining tasks 
demonstrated significant relationships with one or more additional measures in the SCOPE 
battery.  The BLERT demonstrated the greatest number of relationships to other measures in the 
battery (Tables 5a and 5b).  Significant associations were all in the expected direction, and of 
small-to-medium magnitude (range: r=.327-.527). The Eyes task was also the only measure to 
demonstrate a significant relationship with neurocognition (r=.327).  
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Relationship to Functional Outcome  
Correlations between social cognitive and neurocognitive tasks, and functional outcome 
measures for FEP are provided in Table 6.  With the exception of BLERT, Trust, and AIHQ-AB, 
most measures demonstrated significant relationships with one or more outcome measures. 
Significant associations were in the expected direction, and of medium magnitude (range: 
r=.344-.475). 
Incremental Validity 
Social cognition explained additional variance in functional outcome above and beyond 
neurocognition.  Simple linear regression analyses indicated neurocognition, when entered as a 
single predictor variable, accounted for 22% of variance in UPSA-B total scores (adjusted R2 = 
.218, F(1,36) = 11.33, P < .01) and 12% of variance in SSPA ratings (adjusted R2 = .123, F(1,35) 
= 6.039, P < .05), but was not a significant predictor of SLOF self-report values (adjusted R2 = -
.012, F(1,36) = .550, P > .05) (Table 7).  Sequential regression analyses revealed social 
cognition, entered after neurocognition as a second block, accounted for an additional 20% of 
variance in community living skills (UPSA-B; R2 change = .199, P < .05), 19% of variance in 
social skills (SSPA; R2 change = .193, P < .05), and 21% of variance in real-world functioning 
(SLOF-SR; R2 change = .214, P < .01) (Table 7). 
Practicality and Tolerability  
Excluding BLERT administration time (t(75) = 5.78, P = .019, d = .499) and TASIT 
enjoyability ratings (t(74) = 5.06, P = .027, d = -.379), practicality and tolerability did not differ 
significantly between FEP patients and controls (Table 8).  Most measures required <8 minutes 
to complete.  Participants rated all tasks as relatively pleasant (range: M = 4.29 - 5.62). 
Recommendations 
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Regarding suitability for FEP, Hinting was the sole measure to be considered Acceptable 
at Present.  RAD was categorized as Acceptable with Concerns.  Remaining candidate 
measures (AIHQ, BLERT, ER40, Eyes, TASIT, Trust) were regarded as Currently 
Unacceptable.  A comparison between our recommendations and the outcome of the initial 
psychometric evaluation has been provided in Table 9.  A discussion of convergence and 
divergence between studies is provided below. 
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DISCUSSION 
The current study evaluated the psychometric properties of the SCOPE battery for first 
episode psychosis.  Our findings suggest one measure, the Hinting task, was considered 
Acceptable at Present, or appropriate for use with FEP patients.  In addition to displaying 
adequate test-retest reliability and effectively distinguishing between patients and controls, the 
Hinting task also exhibited significant relationships with both performance-based measures of 
functioning. 
The RAD was classified as Acceptable with Concerns and may be cautiously 
considered for use with FEP.  This measure demonstrated adequate test-retest reliability, a 
significant relationship to functioning, minimal practice effects, and limited floor/ceiling effects. 
However, this task was one of the longest to administer and was rated the least enjoyable by 
patients and controls.  RAD’s failure to distinguish patients from controls also tempers 
enthusiasm for this measure.  Modification efforts to develop a shortened version may prove 
beneficial. 
The remaining candidate measures were deemed Currently Unacceptable for use with 
FEP and warrant careful consideration if employed in future clinical trials. Though relatively 
quick and easy to administer, the BLERT and Trust displayed the weakest psychometric 
properties overall, including poor test-retest reliability, failure to differentiate individuals 
with/without psychosis, and limited relation to functioning.  For the ER40 and TASIT, the 
primary concern was inadequate test-retest reliability.  Based on moderate and significant 
practice effects observed for the TASIT, there was also concern about possible interference or 
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non-equivalence between versions.  
Though AIHQ and Eyes demonstrated significant associations with real-world 
functioning, predominantly low test-retest reliability estimates and inability to distinguish 
patients from controls precluded these tasks from recommendation.  Notably, however, one 
subscale of the AIHQ, the BS, was strong on all metrics except group differences.  Prior research 
indicates this subscale of the AIHQ demonstrates adequate psychometric properties, including 
acceptable internal consistency and test-retest reliability estimates; distinguishes patients from 
controls; displays significant relationships to functional outcome, and exhibits associations with 
relevant clinical variables in chronic samples (e.g., hostility and suspiciousness) (Buck et al., 
2017, in press).  The AIHQ-BS may therefore benefit from further examination and use; however 
it will be important to determine if it can be used independently of the rest of the measure. 
Note that measures were required to demonstrate adequate test-retest reliability among 
patients, distinguish patients from controls, and exhibit significant relationships to functioning in 
order to be recommended for use in clinical trials targeting social cognition in FEP.  Given the 
small sample size, we suggest careful consideration of these recommendations and thoughtful 
interpretation of the present findings.  In particular, our recommendations may not be as 
applicable to other research goals (e.g., cross-sectional designs). 
Consistent with Pinkham et al., our data demonstrate that the Hinting task is a 
psychometrically valid theory of mind measure that should be considered appropriate for 
implementation in psychosis research regardless of stage of illness.  Importantly, both Pinkham 
et al. and the present study utilized a more stringent scoring manual.  We emphasize the reported 
psychometric properties as limited to this revised scoring system (available from AEP upon 
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request). Analyses are underway to determine whether the psychometric properties of the task 
may change if the original scoring criteria are utilized.  
Also consistent with the original SCOPE study, our findings substantiate the claim that 
social cognition accounts for more variance in functional outcome than various cognitive factors.  
When measures of social cognition were included in the analyses, the explanatory power of 
neurocognition dropped significantly.  These findings corroborate previous research suggesting 
social cognition mediates the relationship between neurocognition and functioning in psychosis 
(Fett et al., 2011; Schmidt, Mueller & Roder, 2011).  Together, findings from this study provide 
strong support for the importance of social cognition in FEP. 
In contrast, our findings diverge from the initial psychometric evaluation in a number of 
ways.  Although the BLERT displayed some of the strongest properties in SCOPE, it was one of 
the weakest measures when administered to FEP outpatients.  Whereas only two AIHQ subscales 
(HB/AB) showed inadequate test-retest reliability among patients in SCOPE, the Hinting, RAD 
and one subscale of the AIHQ (BS) were the only measures to reach acceptable levels when 
administered to FEP.  Reliability estimates were generally lower for controls than patients in 
SCOPE, while the opposite was observed in our sample.  In addition, excluding one AIHQ 
subscale (AB), all social cognitive tasks adequately differentiated between clinical and normative 
groups in Pinkham et al.  Alternatively, significant group differences were observed for only two 
measures when administered to a younger sample. 
Certain procedural incongruences and sample differences between our study and the 
original SCOPE study may have contributed to lower test-retest reliability estimates, differential 
sensitivity to group differences, and limited relationship to functional outcome.  Effect sizes 
indicating meaningful changes in performance between visits suggested clinically relevant 
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practice effects for half the battery when administered to a younger sample (Table 4b).  Memory 
and practice effects have been shown to adversely affect test-retest reliability (Abner et al., 2012; 
Broglio et al., 2007; Greig et al., 2004).  In fact, educational attainment and general intelligence 
for our patient and control samples were significantly higher than chronic and control 
participants in SCOPE.  Specific differences between our clinical sample and that of SCOPE 
may explain why measures did not reliably differentiate patients and controls, and clarify the 
limited value of most tasks as independent predictors of functional outcome. It is also possible 
that the outcome measures used to assess social functioning and daily living skills may be 
inappropriate for younger patients. 
Psychosis onset typically occurs during late adolescence and early adulthood, a period of 
developmental transition and social/lifestyle changes that may contribute to less stable social 
cognition early in the course of illness (Horan et al., 2012).  To assess the possibility that 
changes in symptom severity between visits may have impacted social cognitive performance, 
we recalculated test-retest correlations controlling for symptom fluctuations. Values were 
unchanged, thus indicating it is unlikely symptom variability accounted for lower test-retest 
reliability estimates. 
 Directly comparing performance between chronic and first episode patient samples 
revealed superior social cognitive abilities for individuals earlier in the course of illness.  FEP 
patients outperformed chronic patients on the majority of tasks, including the AIHQ (BS), Eyes, 
Hinting, RAD and TASIT.  Chronic and FEP patients performed similarly on the remaining 
tasks, including two subscales of the AIHQ subscales (HB/AB), BLERT, ER40 and Trust task.  
When the effects of age and general intelligence were controlled for in the analyses, individuals 
with first episode psychosis exhibited more severe social cognition deficits than matched 
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controls on only two measures of social cognition, the Hinting and TASIT.  These findings 
suggest social cognitive deficits may be less prominent early in the course of illness, are 
potentially mitigated by higher general intelligence, and/or worsen with age.  These findings 
support prior research indicating theory of mind deficits may precede the onset of psychosis and 
should be considered a vulnerability marker of psychosis (Bora & Pantelis, 2013).  It is also 
possible that using total scores, particularly for measures on which items are scored 
dichotomously for correct/incorrect responses, may be scaled in units too gross to detect true, 
though subtler social cognition deficits exhibited by FEP patients in other domains of social 
cognition (Browne et al., 2016; Miller, 2016).  Additional research is needed to clarify the extent 
to which abilities may change over time.  Future studies should also include dual-normative 
comparison groups, carefully consider the impact of relevant covariates on social cognitive 
performance, and longitudinally compare patient performance at different stages of illness. 
 An examination of convergent and divergent validity produced several interesting 
findings.  First, we found a significant, moderate-sized correlation between the Eyes task and the 
neurocognition battery (d = .327, p < .05).  The Eyes task was also shown to be unrelated to 
other candidate measures of social cognition when administered to a younger sample.  These 
findings echo a concern raised by SCOPE investigators and expert consultants indicating 
performance on this task may rely on vocabulary and reading level (Pinkham et al., 2015).  Thus, 
it is unclear whether the Eyes test truly measures theory of mind in psychosis, or if it merely 
functions as an additional measure of neurocognition. 
Similarly, the BLERT was associated with tasks purported to assess various domains of 
social cognition.  These findings align closely with prior research examining the factor structure 
of social cognition in schizophrenia spectrum disorders (Buck, Healey, Gagen, Roberts & Penn, 
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2016).  Specifically, research suggests emotion processing and less complex theory of mind 
abilities tend to be correlated and comprise the “lower-level cue detection” factor of social 
cognition in psychosis (Buck et al., 2016; Mancuso et al., 2011).  Although Pinkham et al. did 
not examine the extent to which the eight social cognitive tasks were related, nor did they present 
correlations between the SCOPE battery and neurocognition, it is unclear whether these 
interpretations can be appropriately translated to chronic schizophrenia research. 
 Finally, certain limitations must be considered.  First, the inclusion of a relatively small 
sample, especially compared to the original psychometric evaluation, is a noteworthy limitation 
of the present study.  Additionally, data were collected from a relatively homogenous sample of 
predominantly white, well-educated males from one of the fastest-growing metropolitan areas in 
the United States.  FEP patients were recruited from a coordinated specialty care clinic focused 
on early intervention and recovery in Chapel Hill, a small university town; and may qualitatively 
differ from clinical samples recruited from more traditional community mental health centers in 
Dallas and Miami, both large urban areas.  Given the various demographic, cognitive, clinical 
and regional differences between our sample and participants involved in SCOPE, interpretations 
of the present findings should be regarded with caution. 
In summary, the present study indicates social cognitive assessment needs to be 
approached differently for individuals early in the course of illness, and investigators should use 
caution when employing tasks that have been used primarily with chronic samples.  This 
underscores the need for the development of new measures for use with FEP, as well as a better 
understanding of how social cognition and functioning may differ across stage of illness.  In 
addition to improving the validity, reproducibility, and comparability of research findings, we 
may use this information to tailor treatment and develop targeted interventions for FEP. 
 27
REFERENCES 
Addington, J, & Piskulic, D.  Social Cognition Early in the Course of the Illness.  In:  
 Roberts D., Penn D. (Eds.), Social Cognition in Schizophrenia.  Oxford University Press, 
New York, pp. 245-262. 
 
Addington, J, Saeedi, H, & Addington, D (2006).  Influence of social perception and  
 social knowledge on cognitive and social functioning in early psychosis.  Br. J. 
Psychiatry, 189 (2006), pp. 373–378. 
 
Adolphs, R., Tranel, D., & Damasio, A. R. (1998). The human amygdala in social  
 judgment. Nature. 393(6684), 470–474. 
 
Barkl, SJ, Lah, S, Harris, A, & Williams, LM. (2014). Facial emotion identification in  
early-onset and first-episode psychosis: A systematic review with meta-analysis.  
Schizophrenia  Research, 159(1), 62-69.  
 
Baron-Cohen S., Wheelwright S., Hill J., Raste Y., & Plumb I. The ‘Reading the Mind in  
the Eyes’ Test revised version: a study with normal adults, and adults with Asperger 
syndrome or high-functioning autism. J Child Psychol Psychiatry, 42, 241–251. 
 
Bell, M., Bryson, G., & Lysaker, P. (1997). Positive and negative affect recognition in  
schizophrenia: A comparison with substance abuse and normal control subjects. 
Psychiatry Research, 73(1-2), 73-82.  
 
Bliksted, V, Fagerlund, B, Weed, E, Frith, C, & Videbech, P (2014).  Social cognition  
and neurocogntive deficits in first-episode-schizophrenia.  Schizophrenia Research, 
153(1-3), 9-17. 
 
Bora, E., & Pantelis, C. (2013). Theory of mind impairments in first-episode psychosis,  
individuals at ultra-high risk for psychosis and in first-degree relatives of schizophrenia: 
Systematic review and meta-analysis. Schizophrenia Research, 144(1-3), 31-36.  
 
Bora, E., Yucel, M., & Pantelis, C. (2009). Theory of mind impairment in schizophrenia:  
meta-analysis. Schizophrenia Research, 109(1–3), 1–9.  
 
Bowie, C.R., Grossman, M., Gupta, M., Oyewumi, L.K., & Harvey, P.D. (2014).  
Cognitive remediation in schizophrenia: efficacy and effectiveness in patients with early 
versus long-term course of illness. Early Interv. Psychiatry, 8(1), 32–38. 
 
Brϋne, M., Abdel-Hamid, M., Lehmkamper, C., & Sonntag, C. (2007).  Mental state  
attribution, neurocognitive functioning, and psychopathology: what predicts poor social 
competence in schizophrenia best?  Schizophrenia Research, 92, 151–159. 
 
Cohen, J. (1988). Statistical power analysis for the behavioral sciences. Erlbaum;  
Hillsdale, NJ. Cohen, J. D., Braver, T. S., & O'Reilly, R. C. (1998). A computational 
 28
approach to prefrontal cortex, cognitive control, and schizophrenia: Recent developments 
and current challenges. In A. C. Roberts, T. W. Robbins, L. Weiskrantz, A. C. Roberts, T. 
W. Robbins, L. Weiskrantz (Eds.), The prefrontal cortex: Executive and cognitive 
functions (pp. 195-220). New York, NY, US: Oxford University Press. 
 
Combs, D. R., Penn, D. L., Wicher, M., & Waldheter, E. (2007). The ambiguous  
intentions hostility questionnaire (AIHQ): A new measure for evaluating hostile social-
cognitive biases in paranoia. Cognitive Neuropsychiatry, 12(2), 128-143. 
 
Corcoran R., Mercer G., & Frith C. D. (1995). Schizophrenia, symptomatology and social  
inference: investigating “theory of  mind” in people with schizophrenia. Schizophrenia 
Research, 17, 5–13. 
 
Corigliano, V., De Carolis, A., Trovini, G., Dehning, J., Di Pietro, S., Curto, M., ... &  
Comparelli, A. (2014). Neurocognition in schizophrenia: From prodrome to multi-
episode illness. Psychiatry research, 220(1), 129-134. 
 
Costello, A. B., & Osborne, J. W. (2005).  Best practices in exploratory factor analysis:  
Four recommendations for getting the most from your analysis.  Practical Assessment, 
Research & Evaluation, 10(7), 1-9. 
 
Couture, S. M., Penn, D. L., Losh, M., Adolphs, R., Hurley, R., & Piven, J. (2010).  
Comparison of social cognitive functioning in schizophrenia and high functioning autism: 
more convergence than divergence. Psychological Medicine, 40(4), 569–579. 
 
Couture, S. M., Penn, D. L., & Roberts, D. L. (2006). The functional significance of  
social cognition in schizophrenia: a review. Schizophrenia bulletin, 32(suppl 1), S44-S63. 
 
Couture S, & Penn D.  Introduction to social cognition in schizophrenia.  In: Roberts D.,  
 Penn D. (Eds.), Social Cognition in Schizophrenia.  Oxford University Press, New York, 
pp. 1-16. 
 
Drost EA. Validity and Reliability in Social Science Research.  Education Research and  
 Perspectives, 38(1): 105-123. 
 
Fett, AJ, Viechtbauer W, Dominguez M, Penn DL, van Os J, Krabbendam L. (2011). The  
relationship between neurocognition and social cognition with functional outcomes in 
schizophrenia: A meta-analysis.  Neuroscience and Biobehavioral Reviews, 35, 573-588. 
 
First, M. B., Spitzer, R. L., Gibbon M., & Williams, J. B.W. (2002). Structured Clinical  
Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-
I/P) New York: Biometrics Research, New York State Psychiatric Institute. 
 
Frith, S. (2008). Social cognition. Philosophical Transactions of the Royal Society,  
363(1499): 2033-2039. 
 
 29
Furr, R.M., & Bacharach, V.R. (2008). Psychometrics: an introduction. Los Angeles:  
Sage Publications. 
 
Fusar-Poli, P., Smieskova, R., Kempton, M. J., Ho, B. C., Andreasen, N. C., &  
Borgwardt, S. (2013). Progressive brain changes in schizophrenia related to antipsychotic 
treatment? A meta-analysis of longitudinal MRI studies. Neuroscience And 
Biobehavioral Reviews, 37(8), 1680-1691. 
 
Green, M. F., Bearden, C. E., Cannon, T. D., Fiske, A. P., Hellemann, G. S., Horan, W.  
 P., & ... Nuechterlein, K. H. (2012). Social cognition in schizophrenia, part 1: 
Performance across phase of illness. Schizophrenia Bulletin, 38(4), 854-864. 
 
Green, M. F., Hellemann, G. S., Horan, W. P., Lee, J., & Wynn, J. K. (2012).  Arch Gen  
 Psychiatry, 69(12): 1216–1224. 
 
Green, M. F., & Leitman, D. I. (2008). Social cognition in schizophrenia. Schizophrenia  
 Bulletin, 34(4), 670–672. 
 
Heinrichs, R. W., & Zakzanis, K. K. (1998). Neurocognitive deficit in schizophrenia: A  
 quantitative review of the evidence. Neuropsychology, 12, 426–445. 
 
Ho, B.C., Andreasen, N.C., Ziebell, S., Pierson, R., & Magnotta, V. (2011). Long-term  
 Antipsychotic Treatment and Brain Volumes: A Longitudinal Study of First-Episode 
Schizophrenia. Archives of General Psychiatry, 68(2), 128–137. 
 
Hooker, C. I., Bruce, L., Lincoln, S. H., Fisher, M., & Vinogradov, S. (2011). Theory of  
 mind skills are related to gray matter volume in the ventromedial prefrontal cortex in 
schizophrenia. Biological Psychiatry, 70(12), 1169–1178. 
 
Horan, W. P., Green, M. F., DeGroot, M., Fiske, A., Hellemann, G., Kee, K., & ...  
 Nuechterlein, K. H. (2012). Social cognition in schizophrenia, part 2: 12-month stability 
and prediction of functional outcome in first-episode patients. 
 
Kay, S. R., Flszbein, A., & Opfer, L. A. (1987). The Positive and Negative Syndrome  
 Scale (PANSS) for Schizophrenia. Schizophrenia Bulletin, 13(2), 261-276. 
 
Kern, R. S., Nuechterlein, K. H., Green, M. F., Baade, L. E., Fenton, W. S., Gold, J. M.,  
... & Stover, E. (2008). The MATRICS Consensus Cognitive Battery, part 2: co-norming 
and standardization. American Journal of Psychiatry. 
 
Kohler, C. G., Walker, J. B., Martin, E. A., Healey, K. M., & Moberg, P. J. (2009). Facial  
emotion perception in schizophrenia: a meta-analytic review. Schizophrenia bulletin, 192. 
 
Kohler C. G., Turner T. H., Bilker W. B., Brensinger, C. M., Siegel, S. J., Kanes, S. J.,  
Gur, R.E., & Gur, R. C. (2003).  Facial emotion recognition in schizophrenia: intensity 
effects and error pattern.  Am J Psychiatry,160, 1768–1774. 
 30
 
Krstev, H., Jackson, H., & Maude, D. (1999). An investigation of attributional style in  
first-episode psychosis. British Journal Of Clinical Psychology, 38(2), 181-194.  
 
Kunda, Z. (1999). Social cognition: Making sense of people. MIT Press; Cambridge,  
MA. 
 
Kurtz, M. M., & Mueser, K. T. (2008).  A Meta-Analysis of Controlled Research on  
Social Skills Training for Schizophrenia.  Journal of Consulting and Clinical Psychology, 
76(3), 491–504. 
 
Lee, R.S., Redoblado-Hodge, M.A., Naismith, S.L., Hermens, D.F., Porter, M.A., &  
Hickie, I.B. (2013). Cognitive remediation improves memory and psychosocial 
functioning in first-episode psychiatric outpatients. Psychol. Med, 43(6), 1161–1173. 
 
Mancuso, F., Horan, W. P., Kern, R. S., & Green, M. F. (2011). Social cognition in  
psychosis: multidimensional structure, clinical correlates, and relationship with functional 
outcome. Schizophrenia research, 125(2), 143-151. 
 
Marchesi, C., Affaticati, A., Monici, A., De Panfilis, C., Ossola, P., Ottoni, R., & Tonna,  
M. (2015). Decrease of functioning in remitted and non-remitted patients 16 years after a 
first-episode schizophrenia. Journal Of Nervous And Mental Disease, 203(6), 406-411. 
 
Martens, L., & Baker, S. (2009).  Promoting Recovery from First Episode Psychosis: A  
 guide for families.  Toronto, Canada: Center for Addition and Mental Health.  
 
Mausbach, B. T., Harvey, P. D., Goldman, S. R., Jeste, D. V., & Patterson, T. L. (2007).   
 Development of a brief scale of everyday functioning in persons with serious mental 
illness. Schizophrenia Bulletin, 33(6), 1364-1372. 
 
McCleery, A., Ventura, J., Kern, R. S., Subotnik, K. L., Gretchen-Doorly, D., Green, M.  
 F., & ... Nuechterlein, K. H. (2014). Cognitive functioning in first-episode schizophrenia: 
MATRICS Consensus Cognitive Battery (MCCB) profile of impairment. Schizophrenia 
Research, 157(1-3), 33-39. 
 
McDonald S., Flanagan S., Rollins J., & Kinch J. (2003). TASIT: a new clinical tool for  
 assessing social perception after traumatic brain injury. J Head Trauma Rehabil, 18, 219–
238. 
 
Mesholam-Gately, R. I., Giuliano, A. J., Goff, K. P., Faraone, S. V., & Seidman, L. J.  
 (2009). Neurocognition in first-episode schizophrenia: A meta-analytic review. 
Neuropsychology, 23(3), 315-336.  
 
Mueser, K.T., Deavers, F., Penn, D.L., & Cassisi, J.E. (2013). Psychosocial treatments  
 for schizophrenia. Annual Review of Clinical Psychology, 9, 465–497. 
 
 31
Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D.,  
 ... & Goldberg, T. (2008). The MATRICS Consensus Cognitive Battery, part 1: test 
selection, reliability, and validity. The American journal of psychiatry, 165(2), 203-213. 
 
Patterson, T. L., Moscona, S., McKibbin, C. L., Davidson, K., & Jeste, D. V. (2001).  
 Social  skills performance assessment among older patients with schizophrenia. 
Schizophrenia research, 48(2), 351-360. 
 
Penn, DL, Corrigan, PW, Bentall, RP, Racenstein, JM, & Newman, L. (1997). Social  
 cognition in schizophrenia. Psychol Bull, 121114–132. 
 
Perkins, D.O., Gu, H., Boteva, K., & Lieberman, J.A. (2005). Relationship between  
 duration of untreated psychosis and outcome in first-episode schizophrenia: A critical 
review and meta-analysis. The American Journal Of Psychiatry, 162(10), 1785-1804. 
 
Pijnenborg, G.H.M., Withaar, F.K., Evans, J.J., Van den Bosch, R.J., Timmerman, M.E.,  
 & Brouwer, W.H. (2009). The predictive value of measures of social cognition for  
 community functioning in schizophrenia: implications for neuropsychological assessment. 
J Int Neuropsychol Soc, 15, 239–247. 
 
Pinkham AE, Penn DL, Green MF, Buck B, Healey K, Harvey PD (2014).  The Social  
 Cognition Psychometric Evaluation study: results of the expert survey and RAND panel.  
Schizophrenia Bulletin, 40(4): 813-823. 
 
Pinkham AE, Penn DL, Green MF, Harvey PD (2015).  Social Cognition Psychometric  
 Evaluation: Results of the Initial Psychometric Study.  Schizophrenia Bulletin. 
 
Prevost, M., Brodeur, M., Onishi, K. H., Lepage, M., & Gold, I. (2015). Judging  
Strangers’ Trustworthiness is Associated with Theory of Mind Skills. Frontiers in 
Psychiatry, 6, 52.  
 
Priebe, S (2007).  Social Outcomes in Schizophrenia.  British Journal of Psychiatry,  
 191(50): s15-s20. 
 
Rabinovitch, M., Béchard-Evans, L., Schmitz, N., Joober, R., & Malla, A. (2009). Early  
 predictors of nonadherence to antipsychotic therapy in first episode psychosis. The  
 Canadian Journal Of Psychiatry / La Revue Canadienne De Psychiatrie, 54(1), 28-35. 
 
Radua, J., Borgwardt, S., Crescini, A., Mataix-Cols, D., Meyer-Lindenberg, A., McGuire,  
 P. K., & Fusar-Poli, P. (2012). Multimodal meta-analysis of structural and functional 
brain changes in first episode psychosis and the effects of antipsychotic medication. 
Neuroscience And Biobehavioral Reviews, 36(10), 2325-2333. 
 
Revell, E.R. Neill, J.C., Harte, M., Khan, Z., & Drake, R.J. (2015).  A systematic review  
 and meta-analysis of cognitive remediation in early schizophrenia.  Schizophrenia 
Research, 168, 213–222. 
 32
 
Romero-Ferreiro, M. V., Aguado, L., Rodriguez-Torresano, J., Palomo, T., Rodriguez- 
 Jimenez, R., & Pedreira-Massa, J. L. (2016). Facial affect recognition in early and late-
stage schizophrenia patients. Schizophrenia Research, 172(1-3), 177-183.  
 
Savla G, Vella L, Armstrong C., Penn D, & Twamley E. (2013). Deficits in domains of  
 social cognition in schizophrenia: A meta-analysis of the empirical evidence. 
Schizophrenia Bulletin, 39, 979–992. 
 
Schmidt, S. J., Mueller, D. R., & Roder, V. (2011). Social cognition as a mediator  
 variable between neurocognition and functional outcome in schizophrenia:  
 empirical review and new results by structural equation modeling. Schizophrenia Bulletin, 
37(suppl 2), S41-S54. 
 
Schneider, L. C., & Struening, E. L. (1983). SLOF: a behavioral rating scale for assessing  
 the mentally ill. In Social Work Research and Abstracts (Vol. 19, No. 3, pp. 9-21). Oxford 
University Press. 
 
Segarra, R., Ojeda, N., Peña, J., García, J., Rodriguez-Morales, A., Ruiz, I., & ...  
 Gutiérrez, M.(2012). Longitudinal changes of insight in first episode psychosis and  
 its relation to clinical symptoms, treatment adherence and global functioning: One-year 
follow-up from the Eiffel study. European Psychiatry, 27(1), 43-49.  
 
Sergi, M. J., Fiske A. P., Horan W. P., Kern, R. S., Kee, K. S., Subotnik, K. L.,  
 Nuechterlein, K. H., & Green, M.F (2009).  Development of a measure of relationship 
perception in schizophrenia. Psychiatry Research, 166(1), 54–62. 
 
Sprong, M., Schothorst, P., Vos, E., Hox, J., & van Engeland, H. (2007). Theory of mind  
in schizophrenia: meta-analysis. Br J Psychiatry, 191, 5–13. 
 
Stouten, L. H., Veling, W., Laan, W., Helm, M., & Gaag, M. (2015). Psychosocial  
functioning in first‐episode psychosis and associations with neurocognition, social 
cognition, psychotic and affective symptoms. Early Intervention In Psychiatry. 
 
Thompson AD, Bartholomeusz C, Yung AR (2011). Social cognition deficits and the  
 ultra-high risk’ for psychosis population: a review of the literature.  Early Intervention in 
Psychiatry, 5, 192-202. 
 
Thompson, A., Papas, A., Bartholomeusz, C., Allott, K., Amminger, G. P., Nelson, B., &  
 ...Yung, A. (2012). Social cognition in clinical 'at risk' for psychosis and first episode 
psychosis populations. Schizophrenia Research, 141(2-3), 204-209. 
 
Ursano, R. J., Bell, C., Eth, S., Friedman, M., Norwood, A., Pfefferbaum, B., … &  
Yager, J. (2004). Practice guideline for the treatment of patients with acute stress disorder 
and posttraumatic stress disorder. Am. J. Psychiatry, 161(11 Suppl.):1–31. 
 
 33
Ventura, J., Ered, A., Gretchen-Doorly, D., Subotnik, K. L., Horan, W. P., Hellemann, G.  
S., & Nuechterlein, K. H. (2015). Theory of mind in the early course of schizophrenia: 
Stability, symptom and neurocognitive correlates, and relationship with functioning. 
Psychological Medicine, 45(10), 2031-2043. 
 
Weickert, T. W., Goldberg, T. E., Gold, J. M., Bigelow, L. B., Egan, M. F., &  
Weinberger, D. R. (2000). Cognitive impairments in patients with schizophrenia 
displaying preserved and compromised intellect. Archives of General Psychiatry, 57(9), 
907-913. 
 
Wu, E. Q., Birnbaum, H. G., Shi, L., Ball, D. E., Kessler, R. C., Moulis, M., & Aggarwal,  
J. (2005). The economic burden of schizophrenia in the United States in 2002. Journal of 
Clinical Psychiatry. 
 
Wykes, T., Reeder, C., Landau, S., Matthiasson, P., Haworth, E., Hutchinson, C., 2009.  
Does age matter? Effects of cognitive rehabilitation across the age span. Schizophr. Res. 
113(2–3), 252–258. 
 
Zaytseva, Y., Burova, V., Garakh, Z., & Gurovich, I. Y. (2013). Attributional style in  
first episode of schizophrenia and schizophrenia spectrum disorders with and without 
paranoid ideation. Psychiatria Danubina, 25(Suppl 2), 329-331. 
 
Yung, A. R., Killackey, E. J., Nelson, B., & McGorry, P. D. (2010). The impact of early  
intervention in schizophrenia. In W. F. Gattaz, G. Busatto, W. F. Gattaz, G. Busatto 
(Eds.): Advances in schizophrenia research 2009 (pp. 299-316). New York, NY, US: 
Springer Science + Business Media. 
  
 34
TABLES 
 
Table 1a. Participant Demographic and Clinical Characteristics (FEP) 
 
 
Characteristic 
FEP Patients  
(n=38) 
FEP Controls 
(n = 39) 
 n (%) n (%) 
Male 33 86.7 32 82.1 
Race     
   Caucasian 29 76.3 29  74.4 
   African American 5 13.2 5 12.8 
   Asian 2 5.3 2 5.1 
   Other 2 5.3 3 7.7 
Ethnicity     
   Hispanic 2 5.3 6 15.4 
   Non-Hispanic 36 94.7 33 84.6 
Diagnosis     
   Schizophrenia 25 65.8   
   Schizoaffective 
   Psychosis NOS 
Medication Type 
   Typical 
   Atypical 
   Combination 
   Unmedicated 
6 
7 
 
1 
32 
2 
3 
15.8 
18.4 
 
2.6 
84.2 
5.3 
7.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Mean SD Mean SD 
Age (years)* 23.45 3.01 23.77 3.39 
Education (years)* 14.03 1.52 15.44 1.80 
Maternal Education 
(years) * 
16.21 2.27 14.85 1.99 
Paternal Education 
(years)* 
17.33 2.33 15.53 2.81 
WRAT-3* 105.87 9.35 107.82 8.91 
UPSA-B* 70.55 11.63 80.53 9.59 
SSPA-Avg. 4.10 .39 4.68 .21 
SLOF-Avg. 4.25 .46 4.61 .24 
PANSS (Visit 1)    
  Positive Total 17.53 4.91  
  Negative Total 16.58 3.96  
  General Total 
  Overall Total 
PANSS (Visit 2) 
  Positive Total 
  Negative Total* 
  General Total* 
  Overall Total* 
36.00 
70.11 
 
14.63 
15.21 
32.92 
62.76 
5.95 
10.37 
 
5.28 
5.58 
10.20 
18.69 
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Table 1b. Participant Demographic and Clinical Characteristics (SCOPE) 
 
 
Characteristic 
SCOPE Patients  
(n=179) 
SCOPE Controls 
(n = 104) 
 n (%) n (%) 
Male 117 65.4 49 47.1 
Race     
   Caucasian 76 76.3 43  41.3 
   African American 94 13.2 55 52.9 
   Asian 4 5.3 4 3.9 
   Other 5 5.3 2 1.9 
Ethnicity     
   Hispanic 37 5.3 21 20.2 
   Non-Hispanic 142 94.7 83 79.8 
Diagnosis     
   Schizophrenia 96 53.6   
   Schizoaffective 
   Psychosis NOS 
Medication Type 
   Typical 
   Atypical 
   Combination 
   Unmedicated 
83 
- 
 
26 
125 
3 
- 
46.4 
- 
 
14.5 
69.8 
1.7 
- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Mean SD Mean SD 
Age (years)* 42.11 12.32 39.20 13.70 
Education (years)* 12.70 2.14 13.43 1.66 
Maternal Education 
(years) * 
12.61 3.22 13.14 2.53 
Paternal Education 
(years)* 
13.04 3.75 13.43 2.49 
WRAT-3* 93.68 15.88 95.35 13.19 
UPSA-B* 69.92 14.33 - - 
SSPA-Avg. 4.22 .62 4.63 .47 
SLOF-Avg. 3.92 .62 4.62 .44 
PANSS (Visit 1)    
  Positive Total 16.14 5.79  
  Negative Total 13.72 5.29  
  General Total 
  Overall Total 
PANSS (Visit 2) 
  Positive Total 
  Negative Total* 
  General Total* 
  Overall Total* 
30.83 
60.69 
 
15.37 
13.51 
29.48 
58.36 
7.99 
15.51 
 
5.07 
5.12 
7.61 
13.79 
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Table 2. Test-Retest Reliability and Internal Consistency 
 Test-Retest Reliability  
(Pearson r) 
Internal Consistency 
(Cronbach’s Alpha) 
Task FEP Patients 
(n=34) 
Controls 
(n=36) 
FEP 
Patients 
(n=38) 
Controls 
(n=39) 
AIHQ     
    Hostility Bias (HB) .529 .394 .497 .387 
    Aggression Bias 
(AB) 
.238 .664 .259 .242 
    Blame Score (BS) .737 .680 .857 .742 
BLERT .455 .665 .740 .411 
ER-40 .496 .705 .599 .538 
Eyes .534 .708 .488 .630 
Hinting .735 .204 .685 .493 
RAD .753 .735 .683 .558 
TASIT .314 .338 .795 .691 
Trust .218 .537 .943 .821 
 
Note: With the outlier included in the analyses, test-retest reliability for the BLERT was .490 
(n=35). 
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Table 3a. Direct comparison of social cognition across studies, part 1 
 
 
 
Task 
SCOPE-FEP Original SCOPE 
Clinical M (SD) Control M (SD) Clinical M (SD) Control M (SD) 
AIHQ-HB 2.02 (.59) 1.89 (.49) 2.38 (.60) 1.99 (.60) 
AIHQ-AB 1.74 (.23) 1.77 (.20) 1.89 (.38) 1.83 (.26) 
AIHQ-BS 7.09 (2.15) 7.09 (1.47) 8.74 (2.81) 7.02 (2.31) 
BLERT 17.14 (2.12) 17.59 (2.04) 13.17 (3.88) 15.75 (2.88) 
ER-40 32.05 (3.54) 33.67 (3.00) 29.55 (5.40) 32.80 (3.54) 
Eyes 25.16 (3.67) 26.54 (4.08) 20.15 (5.46) 23.55 (4.62) 
Hinting 15.82 (2.82) 17.72 (1.78) 13.59 (3.87) 16.82 (2.05) 
RAD 32.34 (4.92) 33.87 (3.95) 24.76 (5.76) 29.82 (5.16) 
TASITA 51.89 (6.24) 57.31 (3.95) 44.43 (7.64) 51.48 (5.62) 
Trust .17 (.83) .39 (.39) -.09 (1.14) .16 (.62) 
 
Notea: BLERT for FEP patients (M=16.74, SD=2.04) when the outlier is included in the analyses 
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Table 3b. Direct comparison of social cognition across studies, part 2 
 
 
Task 
              Main Effects         Interaction 
Phase Group Phase x Group 
AIHQ-HB F(1,354) = 2.85 
p = .092 
F(1,354) = 12.26 
  p = .021 
F(1,354) = 3.72 
p = .055 
AIHQ-AB F(1,354) = 2.58 
p = .109 
F(1,354) = 0.53 
p = .819 
F(1,354) = 1.06 
p = .305 
AIHQ-BS F(1,354) = 1.97 
p = .161 
F(1,354) = 7.23 
p = .008 
F(1,355) = 8.15 
p = .005 
BLERT F(1,353) = 0.78 
p = .379 
F(1,353) = 11.53 
p = .001 
F(1,353) = 6.52 
p = .011 
ER-40 F(1,354) = 0.46 
p = .496 
F(1,354) = 15.65 
p < .001 
F(1,354) = 1.72 
p = .190 
Eyes F(1,355) = 5.27 
p = .022 
F(1,355) = 15.46 
p < .001 
F(1,355) = 4.22 
p = .041 
Hinting F(1,353) = 9.97 
p = .002 
F(1,353) = 39.42 
p < .001 
F(1,353) = 3.14 
p = .077 
RAD F(1,351) = 10.07 
p = .002 
F(1,351) = 24.08 
p < .001 
F(1,351) = 7.97 
  p = .005 
TASITA F(1,355) = 9.25 
p = .003 
F(1,3545) = 59.82 
p < .001 
F(1,355) = 1.18 
p = .278 
Trust F(1,355) = 5.08 
p = .025 
F(1,355) = 3.85 
p = .051 
F(1,355) = .02 
  p = .895 
 
Notea. Analyses were conducted controlling for the effects of age and estimated IQ. 
Noteb: Tests indicating significant interactions and main effects are indicated in bold. 
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Table 4a: Utility as a Repeated Measure, part 1 
 
 
 
Task 
T1 T2 T2-T1 Difference 
Mean SD Mean SD Mean SD 
Patients (n=36) 
AIHQ-HB 1.99 0.577 1.86 0.561 -0.125 0.552 
AIHQ-AB 1.73 0.226 1.77 0.268 -0.047 0.307 
AIHQ-BS 7.1 2.19 7.07 2.29 -0.028 -1.626 
BLERT 17.23 2.14 17.91 1.74 0.686 2.055 
ER-40 32.22 3.55 33.97 2.65 1.75 3.21 
Eyes 25.25 3.74 25.89 3.46 0.639 3.482 
Hinting 15.83 2.87 17.08 2.13 1.25 1.948 
RAD 32.64 4.88 32.19 5.52 -0.444 3.707 
TASIT* 52.03 6.36 49 6.12 -3.028 7.307 
Trust 0.172 0.834 0.198 0.531 0.026 0.885 
  
 Controls (n=36)  
AIHQ-HB 1.86 0.46 1.69 0.539 -0.169 0.55 
AIHQ-AB 1.77 0.195 1.74 0.222 -0.036 0.17 
AIHQ-BS 7.13 1.482 6.59 1.819 -0.544 1.36 
BLERT 17.61 2.032 18.67 1.805 1.056 1.58 
ER-40 33.67 3.089 34.58 2.781 0.917 2.27 
Eyes 26.78 4.134 27.78 3.958 1 3.098 
Hinting 17.92 1.538 18 1.639 0.083 2.005 
RAD 34.08 4.003 36.19 3.984 2.111 2.906 
TASIT* 57.75 3.667 53.47 5.955 -4.278 5.843 
Trust 0.394 0.392 0.327 0.413 -0.067 0.388 
 
*Note: Alternate versions were used for the TASIT  
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Table 4b: Utility as a Repeated Measure, part 2 
 
 
 
Task 
 
Number at Floor/Ceiling 
  
 
  
T1 T2 t p value Cohen’s dz 
  Patients (n=36)  
AIHQ-HB -- -- -1.359 0.183 0.226 
 
AIHQ-AB -- -- -0.924 0.362 0.153 
 
AIHQ-BS 
 
-- -- -0.102 0.919 0.017 
BLERT 1/0 0/1 1.974 0.057 0.351 
ER-40 0/0 0/0 3.271 0.002 0.545 
Eyes 2/0 2/0 1.101 0.278 0.184 
Hinting 1/2 0/2 3.851 <.001 0.642 
RAD 1/0 2/0 0.719 0.477 0.12 
TASIT* 1/0 0/1 -2.486 0.018 0.414 
 
Trust -- -- 0.179 0.859 0.029 
   Controls (n=36) 
AIHQ-HB -- -- -1.836 0.075 0.307 
 
AIHQ-AB -- -- -1.255 0.218 0.212 
 
AIHQ-BS -- -- -2.41 0.021 0.4 
 
BLERT 0/2 0/5 3.997 <.001 0.668 
ER-40 0/0 0/0 2.42 0.021 0.404 
Eyes 1/0 1/0 1.936 0.061 0.323 
Hinting 0/4 0/3 0.249 0.805 0.041 
RAD 0/0 0/0 4.359 <.001 0.726 
TASIT* 0/0 0/2 -4.392 <.001 0.732 
Trust -- -- -1.091 0.282 0.173 
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Table 5a. Correlations between Candidate Measures of Social Cognition and  
Neurocognition, part 1 
 
 
Task 
 
AIHQ-HB 
 
AIHQ-AB 
 
AIHQ-BS 
 
BLERT 
 
ER-40 
 
AIHQ-HB -- 0.247 .527** -0.211 -0.116 
AIHQ-AB 0.247 -- .461** .380* .422** 
AIHQ-BS .527** .461** -- 0.005 0.007 
BLERT -0.211 .380* 0.005 -- .520** 
ER-40 -0.116 .422** 0.007 .520** -- 
Eyes -0.166 -0.2 -0.093 0.264 0.259 
Hinting -0.196 0.267 0.035 .410* .391* 
RAD 0.015 0.096 0.034 .340* 0.311 
TASIT -0.168 0.149 0.179 0.084 0.077 
Trust -0.057 -0.15 -0.246 .443** -0.076 
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Table 5b. Correlations between Candidate Measures of Social Cognition and  
Neurocognition, part 2 
 
 
Task 
 
Eyes 
 
Hinting 
 
RAD 
 
TASIT 
 
Trust MCCB 
Composite 
AIHQ-HB -0.166 -0.196 0.015 -0.168 -0.057 -0.046 
AIHQ-AB -0.2 0.267 0.096 0.149 -0.15 -0.136 
AIHQ-BS -0.093 0.035 0.034 0.179 -0.246 -0.076 
BLERT 0.264 .410* .340* 0.174 .443** 0.065 
ER-40 0.259 .391* 0.311 0.077 -0.076 0.11 
Eyes -- 0.251 0.305 0.165 0.042 .327* 
Hinting 0.251 -- 0.281 .522** -0.304 0.176 
RAD 0.305 0.281 -- .327* -0.064 0.253 
TASIT 0.165 .522** .327* -- -0.277 0.111 
Trust 0.042 -0.304 -0.064 -0.277 -- 0.08 
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Table 6. Correlations between Social Cognitive and Neurocognitive Tasks and Functional 
Outcome Measures in Patients 
 
 UPSA Total SSPA Average SLOFSR Average  
Social Cognitive    
  AIHQ-HB  -.096 -.162 -.360* 
  AIHQ-AB  .136 .069 -.253 
  AIHQ-BS  .158 .053 -.372* 
  BLERT  .265 .159 .138 
  ER-40  .337* .435** -.101 
  Eyes  .326* .234 .407* 
  Hinting  .372* .473** .189 
  RAD  .456** .344* .020 
  TASIT .475** .179 .205 
  Trust  -.037 -.252 .161 
Neurocognitive    
  MCCB Composite .489** .384* .123 
* p<.05, ** p<.01 
 
Notea: There was an error with scene two for the SSPA role-play for one SCZ participant.  
This particular individual’s data – the average for scene 1 only – were included in the above 
analyses. 
Noteb: All participants completed the self-report (SR) version of the SLOF.  Informants were 
identified for each SCZ participant, though only 25 individuals successfully completed the 
informant version of the measure.  Neither performance on the social cognition measures nor 
scores on the social functioning measures were significantly related to the informant version 
of the SLOF. 
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Table 7. Regression Models Summarizing Independent and Combined Contributions of 
Neurocognition and Social Cognition to Outcomes  
Neurocognition only 
MCCB 
Composite 
R2 Adjusted R2 F p     
UPSA total .239 .218 11.334 .002     
SSPA average .147 .123 6.039 .019     
SLOFSR average .015 -.012 .550 .463     
 Social Cognition only   
SC Tasks R2 Adjusted R2 F p b* t p sr2 
UPSA total .392 .297 4.12 .005     
  ER-40      .198 1.241 .224 .029 
  Eyes      .143 .963 .343 .018 
  Hinting      .007 .041 .968 .000 
  RAD      .233 1.486 .147 .042 
  TASIT     .357 2.099 .044 .084 
SSPA average .323 .262 5.26 .004     
  ER-40      .254 1.588 .122 .052 
  Hinting     .325 2.054 .048 .086 
  RAD     .172 1.124 .269 .026 
SLOFSR 
average 
.298 .236 4.82 .007     
  AIHQ-HB      -.169 -.991 .329 .020 
  AIHQ-BS      -.250 -1.478 .149 .045 
  Eyes      .356 2.442 .020 .123 
Neurocognition and Social Cognition 
 
  UPSA-B  SSPA             SLOFSR 
 b* sr2 b* sr2 b* sr2 
Block 1 - Neurocognition       
   MCCB Composite .373** .120** .274 .069 -.023 .000 
Block 2 – Social Cognition       
  AIHQ-HB -- -- -- -- -.168 .020 
  AIHQ-AB  
  AIHQ-BS 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
-.251 
-- 
.045 
  ER-40  .216 .035 .257 .053 -- -- 
  Eyes  .043 .001 -- -- .363* .115* 
  Hinting  -.030 .001 .294 .070 -- -- 
  RAD  .169 .022 .106 .009 -- -- 
  TASIT .371* .091* -- -- -- -- 
Overall Model       
  Adjusted R2 .417*  .316*  .214**  
  R2 Change .199*  .193*  .214**  
* p<.05, ** p<.01 
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Table 8. Practicality and Tolerability 
 
 Practicality (Administration Time in 
Minutes) 
Tolerability (Participant Ratings) 
Task Patients (n=38) Controls (n=39) Patients (n=38) Controls (n=39) 
 Mean SD Mean SD Mean SD Mean SD 
AIHQ 6.98 1.35 6.16 1.16 5.41 1.22 5.60 0.95 
BLERT  7.72 1.47 7.14 0.76 5.21 1.53 5.23 1.29 
ER-40  3.46 0.83 2.60 0.57 5.39 1.31 5.62 0.99 
Eyes  7.20 1.97 5.14 1.76 5.09 1.52 5.23 1.14 
Hinting  7.95 1.66 6.85 1.34 4.83 1.36 5.37 1.33 
RAD  16.80 3.16 14.53 3.38 4.29 1.39 4.96 1.13 
TASIT 20.40 2.86 18.80 2.29 4.92 1.46 5.39 1.01 
Trust  4.53 1.39 3.61 1.04 5.42 1.46 5.56 1.05 
Note: These ratings are from the first administration of each SC task only. 
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Table 9. Comparison of our Findings with the Preliminary Findings from SCOPE 
 
       
Task 
Test-
retest 
Internal 
Consistency  
Utility as 
Repeated 
Measure 
Rel. to 
Functioning 
Group 
Differences 
Admin. 
Time < 
10 min. 
Rec. for 
Use 
 SCOPE-FEP 
AIHQ-HB X X ✓  ✓  X ✓  X 
AIHQ-AB X X ✓  X X ✓  X 
AIHQ-BS ✓  ✓  ✓  ✓  X ✓  X 
BLERT X X ✓  X X ✓  X 
ER-40 X X X ✓  X ✓  X 
Eyes X X ✓  ✓  X ✓  X 
Hinting ✓  X X ✓  ✓  ✓  ✓  
RAD ✓  X ✓  ✓  X X ✓  
TASIT X ✓  X ✓  ✓  X X 
Trust X ✓  ✓  X X ✓  X 
 Original SCOPE 
AIHQ-HB X ✓  ✓  X ✓  ✓  X 
AIHQ-AB X X ✓  X X ✓  X 
AIHQ-BS ✓  X ✓  X ✓  ✓  X 
BLERT ✓  X ✓  ✓  ✓  ✓  ✓  
ER-40 ✓  ✓  ✓  ✓  ✓  ✓  ✓  
Eyes ✓  X ✓  ✓  ✓  ✓  ✓  
Hinting ✓  X ✓  ✓  ✓  ✓  ✓  
RAD ✓  X X ✓  ✓  X X 
TASIT ✓  ✓  ✓  ✓  ✓  X ✓  
Trust ✓  ✓  ✓  X ✓  ✓  X 
 
 
